1 Min Read
Dec 14 (Reuters) - U.S. Food and Drug Administration (FDA):
* Approves Eucrisa for eczema
* Eucrisa should not be used in patients who have had a hypersensitivity reaction to Eucrisa’s active ingredient, crisaborole Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.